[
  {
    "ts": null,
    "headline": "JPMorgan reveals 9 stocks with major problems",
    "summary": "These surprising names look riskier than they seem",
    "url": "https://finnhub.io/api/news?id=0ea1148ffc1ccaf4cd528fe9efe0002d7efa351cd4cedf9bd5518448027d43fb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752536220,
      "headline": "JPMorgan reveals 9 stocks with major problems",
      "id": 135958368,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "These surprising names look riskier than they seem",
      "url": "https://finnhub.io/api/news?id=0ea1148ffc1ccaf4cd528fe9efe0002d7efa351cd4cedf9bd5518448027d43fb"
    }
  },
  {
    "ts": null,
    "headline": "Why Moderna (MRNA) Stock Is Falling Today",
    "summary": "Shares of biotechnology company Moderna (NASDAQ:MRNA) fell 3.6% in the morning session after JPMorgan added the stock to its list of top short ideas for the second half of 2025.",
    "url": "https://finnhub.io/api/news?id=1ad407c7d8b59d202caf23fca8e599753bfe1ece89494a94088f52ec7869e2e9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752520860,
      "headline": "Why Moderna (MRNA) Stock Is Falling Today",
      "id": 135937776,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "Shares of biotechnology company Moderna (NASDAQ:MRNA) fell 3.6% in the morning session after JPMorgan added the stock to its list of top short ideas for the second half of 2025.",
      "url": "https://finnhub.io/api/news?id=1ad407c7d8b59d202caf23fca8e599753bfe1ece89494a94088f52ec7869e2e9"
    }
  },
  {
    "ts": null,
    "headline": "FDA Accepts GSK Filing for Expanded Use of RSV Shot in Younger Adults",
    "summary": "FDA accepts GSK's filing to extend Arexvy's RSV vaccine use to high-risk adults under 50, with a decision due in 2026.",
    "url": "https://finnhub.io/api/news?id=0b28c245c37994714e1bc6d07a76677aea276d00e47ba6c90b00cf0910762d74",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752502320,
      "headline": "FDA Accepts GSK Filing for Expanded Use of RSV Shot in Younger Adults",
      "id": 135929797,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "FDA accepts GSK's filing to extend Arexvy's RSV vaccine use to high-risk adults under 50, with a decision due in 2026.",
      "url": "https://finnhub.io/api/news?id=0b28c245c37994714e1bc6d07a76677aea276d00e47ba6c90b00cf0910762d74"
    }
  },
  {
    "ts": null,
    "headline": "What to Expect From Moderna's Next Quarterly Earnings Report",
    "summary": "Moderna is expected to announce its second-quarter results in the upcoming month, and analysts expect a slight reduction in its losses.",
    "url": "https://finnhub.io/api/news?id=330cd8e6f108be51c36b69c42cbc1660925ea699efca3a538ecc75ce42f02d37",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752477255,
      "headline": "What to Expect From Moderna's Next Quarterly Earnings Report",
      "id": 135921360,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "Moderna is expected to announce its second-quarter results in the upcoming month, and analysts expect a slight reduction in its losses.",
      "url": "https://finnhub.io/api/news?id=330cd8e6f108be51c36b69c42cbc1660925ea699efca3a538ecc75ce42f02d37"
    }
  },
  {
    "ts": null,
    "headline": "GSK seeks FDA nod for expanded use of RSV vaccine in adults",
    "summary": "If approved in the world's biggest pharmaceuticals market, GSK's vaccine, Arexvy, would be competing for a market share in the 18-49 age group with Moderna's mRESVIA and Pfizer's Abrysvo.  RSV is a common respiratory virus that causes seasonal infections such as the flu and is a leading cause of pneumonia and death in infants and older adults.  GSK's vaccine is currently approved in the U.S. for preventing RSV-related disease in adults aged 60 and above, and in at-risk adults aged 50 to 59.",
    "url": "https://finnhub.io/api/news?id=a1126203e4029088cdfb663cf66ee0afb37a9cd23f7d9a9f413593759e0047cd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752475328,
      "headline": "GSK seeks FDA nod for expanded use of RSV vaccine in adults",
      "id": 135920860,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "If approved in the world's biggest pharmaceuticals market, GSK's vaccine, Arexvy, would be competing for a market share in the 18-49 age group with Moderna's mRESVIA and Pfizer's Abrysvo.  RSV is a common respiratory virus that causes seasonal infections such as the flu and is a leading cause of pneumonia and death in infants and older adults.  GSK's vaccine is currently approved in the U.S. for preventing RSV-related disease in adults aged 60 and above, and in at-risk adults aged 50 to 59.",
      "url": "https://finnhub.io/api/news?id=a1126203e4029088cdfb663cf66ee0afb37a9cd23f7d9a9f413593759e0047cd"
    }
  }
]